Moderna is well positioned for growth now that it is experiencing more stable commercial demand, with disciplined execution strengthening the company's commercial engine, pipeline advancement across diseases with high unmet need, and a manufacturing network purpose-built for mRNA. The company plans to build a large seasonal vaccine franchise for at-risk populations and invest cash generated into oncology and rare disease therapeutics, delivering up to 10% revenue growth in 2026 while reducing R&D investments and diversifying into oncology.
Cyborg Score Rationale
The company faces revenue decline with three-year revenue growth of -41.3%, negative net margin of -141.51%, and operating margin of -157.27%, indicating substantial operational challenges. However, Moderna's Phase 2b melanoma vaccine shows 49% risk reduction and advances eight Phase 2/3 trials across multiple cancer types with full enrollment in pivotal studies.
Top Insights
2026 targets up to 10% sales growth driven by geographic partnerships in UK, Canada and Australia, and launches of higher-efficacy COVID and flu products.
Moderna will not fund new late-stage Phase III infectious-disease vaccine trials, citing shrinking U.S. market and regulatory slowdowns, reallocating resources to oncology and rare-disease programs.
The company secured a $1.5 billion term loan and expects cash costs of approximately $4.2 billion in 2026, advancing toward targeted cash breakeven in 2028.
GSK filed lawsuit in November 2024 alleging Moderna's COVID-19 and RSV vaccines infringe on GSK's patents related to mRNA lipid nanoparticle delivery technology.
Named Competitors
Comirnaty — Leading COVID-19 mRNA vaccine
Nvaxovid — Protein-based COVID-19 vaccine alternative
KEYTRUDA — Cancer immunotherapy partner for intismeran combination
mRNA Therapeutics Pipeline — Strategic partner in mRNA-based treatments
Recent Developments
(Feb 2026) Moderna's five-year Phase 2b melanoma data showing 49% reduction in recurrence/death risk with intismeran + KEYTRUDA scheduled for early 2026 readout
(Jan 2026) FDA issued multiple breakthrough designations for precision biologics and mRNA platforms in oncology applications
(Nov 2025) 2025 pre-audited sales of $1.9 billion exceeded guidance midpoint; cash costs reduced by nearly $2 billion year-over-year to $4.3-4.5 billion
(Sep 2025) Marlborough, Massachusetts facility for intismeran personalized cancer vaccine began clinical batch supply with commercial launch preparation underway
Open the full interactive Moderna, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.